09:29 AM EDT, 06/17/2024 (MT Newswires) -- Mustang Bio ( MBIO ) shares were up nearly 195% in recent Monday premarket activity after the company said that updated data from its phase 1/2 clinical trial of MB-106 indicated a 90% overall response rate in Waldenstrom macroglobulinemia blood cancer patients previously treated with Bruton's tyrosine kinase inhibitors.

The company said that three of 10 patients in the trial showed complete responses, adding that one of these three has been in complete remission for 31 months. Two participants demonstrated "very good" partial responses, and four showed partial responses, Mustang Bio ( MBIO ) said.

Mustang Bio ( MBIO ) also said nine patients experienced cytokine release syndrome during the study, while one patient had grade 1 immune effector cell-associated neurotoxicity syndrome. There were no grade 3 or 4 cases of CRS or grade 2, 3, or 4 ICANS observed, the company added.

Price: 0.3832, Change: +0.25, Percent Change: +194.77